Drug Profile
Zotarolimus - AbbVie
Alternative Names: ABT 578; Endeavor; Endeavor Resolute; MDT-4107 DES; Resolute DES; Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System (34/38 mm); Resolute Onyx; ZoMaxx; Zotarolimus-eluting coronary stent systemLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie; Medtronic
- Class Erectile dysfunction therapies; Lactones; Macrolides; Polyenes; Tetrazoles; Vascular disorder therapies
- Mechanism of Action MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Coronary artery restenosis
- No development reported Erectile dysfunction
- Discontinued Vascular restenosis
Most Recent Events
- 22 Apr 2021 Medtronic completes the Onyx ONE Clear clinical trial for Coronary artery restenosis in USA and Japan (NCT03647475)
- 09 Oct 2020 Medtronic Vascular completes the Onyx ONE trial in Coronary artery restenosis in Australia, Austria, Belgium, Bulgaria, France, Hong Kong, Ireland, Italy, Korea, Latvia, Lithuania, Malaysia, Netherlands, New Zealand, Norway, Poland, Singapore, Slovakia, Spain, Sweden, Switzerland, Thailand and in the UK (NCT03344653)
- 30 Mar 2020 Safety data from the Onyx ONE Clear clinical trial for Coronary artery released by Medtronic